PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
PolyPid Ltd. has completed the New Drug Application submission to the FDA for D-PLEX100, its lead product candidate aimed at preventing surgical site infections in colorectal surgery patients. The submission follows positive Phase 3 trial results showing a 60% reduction in infection risk and the drug currently holds multiple FDA designations includ…